Recent Updates
Recently added Catalysts
CTNM Positive Sentiment

Active MS lesions are characterized by high LPA1 expression and PIPE-791 promotes remyelination via LPA1 inhibition in the cuprizone model

Sunday, March 17, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The research presented at the Gordon Research Conference 2024 highlights the role of high LPA1 expression in active multiple sclerosis (MS) lesions. It also discusses the potential of PIPE-791 in promoting remyelination through LPA1 inhibition in a cuprizone model. This study may provide new insights into MS treatment strategies.

Market Sentiment Analysis

POSITIVE FACTORS

  • High LPA1 expression is linked to active MS lesions.
  • PIPE-791 shows promise in promoting remyelination.
  • Research presented at a reputable conference.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+79%
120-day peak, hindsight
Typical move
6.4%
average across 3 past catalysts
Cash runway
~61 mo
Minimal dilution risk
Lead asset
PIPE-307 Dose A
Phase 2 · Relapsing Remitting Multiple Sclerosis

Full Press Release Details

Didier Bagnol, Alexander R Broadhead, Geraldine C Edu, John Atkins, Christopher S Baccei, Kym I Lorrain, Michael M Poon, Jeffrey R Roppe, Thomas O Schrader, Lino J Valdez, Yifeng Xiong, Austin C Chen, Daniel S Lorrain
Presented at Gordon Research Conference (GRC) 2024

Frequently Asked Questions

What is the significance of LPA1 in MS lesions?

High LPA1 expression is associated with active multiple sclerosis lesions.

How does PIPE-791 affect remyelination?

PIPE-791 promotes remyelination by inhibiting LPA1.

Where was this research presented?

The research was presented at the Gordon Research Conference 2024.

ShareAdd on Google
Tags: CTNM Viatris Investor Conferences Healthcare LPA1 PIPE-791 remyelination multiple sclerosis Gordon Research Conference
Last updated: Mar 17, 2024

Biotech snapshot

Cash runway
$237M liquidity · $4M/mo burn
~61 mo
Minimal dilution risk
Lead asset
PIPE-307 Dose APhase 2
Relapsing Remitting Multiple Sclerosis →

Catalyst track record

+79%
best trade around CTNM's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for CTNM.

See every catalyst's timing & PoA →